Company intelligence
Apheris
Life sciences data networks for AI
About Apheris
Apheris delivers enterprise-grade AI applications for drug discovery, designed for pharma companies to run and customize securely within their own IT environments. By keeping all data local, organizations maintain full sovereignty over IP-sensitive assets. These local deployments also serve as the foundation for Apheris-hosted federated data networks, where pharma companies collaboratively train and benchmark models on proprietary datasets to unlock more robust and generalizable models for drug discovery.
Verified activity
Signals from Apheris
12 published signals
Presence & Recognition
Apheris presented at NVIDIA FLARE Day on federated training to improve protein-ligand co-folding models.
Reported by Nicolas Gautier
People
Apheris is hiring a Senior ML Research Engineer to build co-folding and binding-affinity models for molecular and structural biology.
Reported by Robin Roehm
People
Apheris welcomed Pedro Casal Ribeiro as Agentic AI Engineer.
Reported by Apheris
People
Apheris welcomed Maranga M. as Forward-Deployed ML Engineer.
Reported by Apheris
People
Apheris welcomed Joe Phillips as Talent Acquisition Partner.
Reported by Apheris
People
Apheris welcomed Erin Woggon as Operations Manager and Executive Assistant.
Reported by Apheris
People
Apheris welcomed Egor Marin as Forward-Deployed ML Engineer.
Reported by Apheris
Research & Knowledge
Apheris released OpenBind-0, an open co-folding model that ships with 717 ligand-bound structures from fragment-to-hit campaigns on three real discovery targets.
Reported by Robin Roehm
Research & Knowledge
Apheris achieved a top-25 success rate of 92% on the EV-A71 2A protease using OpenBind-0, which was trained on four years of the PDB from 2021 to 2025.
Reported by Robin Roehm
Research & Knowledge
Apheris achieved a top-25 success rate of 28% on the herbicide target FatA using OpenBind-0, which was trained on four years of the PDB from 2021 to 2025.
Reported by Robin Roehm
Research & Knowledge
Apheris achieved a top-25 success rate of 10% on the RdRp domain of Dengue and Zika NS5 using OpenBind-0, which was trained on four years of the PDB from 2021 to 2025.
Reported by Robin Roehm
Presence & Recognition
Apheris is featured in a new BioCentury Inc. piece by Lindsay Martin, PhD on how far federated learning can go in drug discovery.
Reported by Apheris